RxDoctor Payments DataLook up a doctor →

Ashley Amedee, NP

Nurse Practitioner · Baton Rouge, LANPI 1962719690

Payments from drug & device makers

$9,351in general payments, 2019–2025

Across 508 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$905
  • Novo Nordisk$808
  • Boehringer Ingelheim$702
  • Lilly USA, LLC$661
  • Pfizer$620
  • Abbott$555
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$9,337100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,351 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$47,823
Medicare patients
206
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$120,509
OzempicSemaglutide56$70,965
MounjaroTirzepatide47$52,043
TrulicityDulaglutide23$40,956
FarxigaDapagliflozin Propanediol19$26,382
EliquisApixaban18$25,326
LinzessLinaclotide11$15,162
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$13,753
Soliqua 100-33Insulin Glargine/Lixisenatide19$13,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,480
Atorvastatin Calcium376$3,175
Rosuvastatin Calcium207$2,748
Albuterol Sulfate HfaAlbuterol Sulfate77$2,408
Olmesartan Medoxomil157$2,156
SynthroidLevothyroxine Sodium33$1,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$702$120,509106 claims
Lilly USA, LLCMounjaro, Trulicity$661$92,99970 claims
Novo NordiskOzempic$808$70,96556 claims
AstraZenecaFarxiga$287$26,38219 claims
PfizerEliquis$620$25,32618 claims
AbbVieLinzess, Synthroid$341$17,13944 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$248$13,44319 claims
GSKTrelegy Ellipta$905$8,48013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →